Kezar Life Sciences Inc (KZR NASDAQ) stock market data APIs
$0.1559
-0(-0%)
as of May 22, 2026
Try our APIs with
free plan!
Kezar Life Sciences Inc Financial Data Overview
Price chart is built with
Anychart
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Prev. Close
0.1559
Open
0.1549
High
0.156
Low
0.1543
52 wk Range
0.14-7.55
Market Cap
53 856 K
Shares Outstanding
7 388 K
EPS
-0.7004
Beta
0.406
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kezar Life Sciences Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kezar Life Sciences Inc data using free add-ons & libraries
Get Kezar Life Sciences Inc Fundamental Data
Kezar Life Sciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -51 373 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-31
- EPS/Forecast: -0.98
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kezar Life Sciences Inc News
New
Halper Sadeh LLC is Investigating Whether KZR, QXO, SKYT are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Sharehold...
Weekly Buzz: SPRY Gains FDA Nod; EU Expands Kerendia Label; LLY Acquires CNTA; BIIB Snaps Up APLS
(RTTNews) - This week's biotech landscape witnessed regulatory approvals across the U.S., EU, and China, acquisitions, a few key trial goal misses and positive clinical trial data readouts across ther...
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California, March 30, 2026--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on deliveri...
Kezar Life Sciences: FDA Division Grants Type C Meeting To Discuss Development Of Zetomipzomib
(RTTNews) - Kezar Life Sciences (KZR) said the FDA Division of Hepatology and Nutrition has granted the company a Type C meeting for the first quarter to discuss the development of zetomipzomib, a sel...
Get Kezar Life Sciences Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
